Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.55 |
| ▸ | FLT3 | P36888 | 5/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23201680 | 0.89 | MAPK14 (0.78) | MAPK14NPC1RAB9AMAPK13FLT3 | |
| SCHEMBL29844532 | 0.86 | MAPK14 (1.00) | MAPK14NPC1RAB9AMAPK13 | |
| SCHEMBL23201670 | 0.86 | MAPK14 (1.00) | MAPK14NPC1RAB9AMAPK13 | |
| SCHEMBL23201656 | 0.84 | MAPK14 (0.75) | MAPK14MAPK13 | |
| SCHEMBL29844348 | 0.83 | MAPK14 (1.00) | MAPK14NPC1RAB9AMAPK13FLT3 | |
| SCHEMBL23637682 | 0.83 | MAPK14 (1.00) | MAPK14NPC1RAB9AMAPK13FLT3 | |
| SCHEMBL25641497 | 0.81 | MAPK14 (0.87) | MAPK14NPC1RAB9AMAPK13 | |
| SCHEMBL23201709 | 0.81 | MAPK14 (0.80) | MAPK14MAPK13FLT3 | |
| SCHEMBL23201663 | 0.80 | MAPK14 (0.74) | MAPK14MAPK13 | |
| SCHEMBL23201752 | 0.80 | MAPK14 (0.77) | MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802525-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2021-04-14 | — | — | EP | claimed |
| US-12006337-B2 | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2024-06-11 | — | — | US | disclosed |
| EP-4219489-A2 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006337-B2 | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885NPC1 3723/4885RAB9A 1675/4885 |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885NPC1 3723/4885RAB9A 1675/4885 |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885NPC1 3723/4885RAB9A 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.